Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q14766
UPID:
LTBP1_HUMAN
Alternative names:
Transforming growth factor beta-1-binding protein 1
Alternative UPACC:
Q14766; A1L3V1; P22064; Q53SD8; Q53SF3; Q53SG1; Q59HF7; Q8TD95
Background:
Latent-transforming growth factor beta-binding protein 1 (LTBP-1) is a crucial regulator of TGF-beta, a key player in cell growth, differentiation, and repair. It ensures TGF-beta remains inactive in the extracellular matrix, a vital process for controlled cellular functions. LTBP-1's interaction with TGF-beta's regulatory chain, the Latency-associated peptide (LAP), and its competition with LRRC32/GARP highlight its significant role in TGF-beta pathway regulation.
Therapeutic significance:
LTBP-1's involvement in Cutis laxa, autosomal recessive, 2E, characterized by skin laxity and connective tissue weakness, underscores its potential as a therapeutic target. Understanding LTBP-1's function could pave the way for innovative treatments for connective tissue disorders.